None listed
Conditions
Interventions
Drug : Tocilizumab: Administer 8 mg/kg intravenously or subcutaneously over 1 hour (maximum dose of 800 mg). May be repeated after a minimum of 8 hours, up to a maximum of 2 doses within a 24-hour per
Sponsors
The Catholic University of Korea, Seoul St. Mary's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Male or female patients aged 19 years or older. 2)Patients diagnosed with Multiple Myeloma who have been previously treated with at least one Proteasome Inhibitor, one Immunomodulatory Agent, and one Monoclonal Antibody therapy (i.e., patients exposed to all three major classes of immunotherapies). 3)Patients diagnosed with Relapsed/Refractory Multiple Myeloma (RRMM) during the period from the IRB approval date until December 2025, and who are scheduled to initiate treatment with a bispecific antibody within one month of screening. 4)Subjects who have received a detailed explanation of this study, have voluntarily decided to participate, and have provided written informed consent to comply with the study requirements.
Exclusion criteria
Exclusion criteria: 1) Those who do not consent to participate in the study 2) Patients diagnosed with a plasma cell disorder other than multiple myeloma (e.g., lymphoma, POEMS syndrome) 3) Those who cannot read and understand documents written in Korean
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the incidence and severity | — |
Secondary
| Measure | Time frame |
|---|---|
| the differences in dosing schedule and operational practices;the antitumor efficacy;quality of life and functional;the changing patterns of PRO;To compare the efficacy and adverse effects of standard-of-care (SOC) drugs with the same indications and dual antibodies.;Assess the association between immune and genomic biomarkers and clinical indicators. | — |
Countries
Korea, Republic of
Contacts
Public ContactSeungMin Jun
The Catholic University of Korea, Seoul St. Mary's Hospital
Outcome results
None listed